Another study suggests that the postmenopausal women who were treated with aromatase inhibitors and took topical estrogen treatment for the vaginal symptoms secondary to aromatase inhibitors showed poor systematic uptake indicating an indirect to decrease the suspicion of using this topical hormonal therapy and breast cancer recurrence [187]. The gene discussed is CYP19A1; the disease is breast carcinoma.